6.
Bechmann N, Moskopp M, Ullrich M, Calsina B, Wallace P, Richter S
. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocr Relat Cancer. 2020; 27(11):625-640.
DOI: 10.1530/ERC-20-0205.
View
7.
Molenaar J, Koster J, Zwijnenburg D, van Sluis P, Valentijn L, van der Ploeg I
. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483(7391):589-93.
DOI: 10.1038/nature10910.
View
8.
Eisenhofer G, Pamporaki C, Lenders J
. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocr Rev. 2023; 44(5):862-909.
DOI: 10.1210/endrev/bnad011.
View
9.
Jha A, Patel M, Carrasquillo J, Ling A, Millo C, Saboury B
. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Ga-DOTATATE, FDG, F-FDOPA, and F-FDA). AJR Am J Roentgenol. 2021; 218(2):342-350.
PMC: 10389669.
DOI: 10.2214/AJR.21.26071.
View
10.
Patel M, Jha A, Ling A, Chen C, Millo C, Kuo M
. Performances of Functional and Anatomic Imaging Modalities in Related Metastatic Pheochromocytoma and Paraganglioma. Cancers (Basel). 2022; 14(16).
PMC: 9406057.
DOI: 10.3390/cancers14163886.
View
11.
Fishbein L, Khare S, Wubbenhorst B, DeSloover D, DAndrea K, Merrill S
. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015; 6:6140.
PMC: 4302757.
DOI: 10.1038/ncomms7140.
View
12.
Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I
. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J. 2019; 38(19):e96659.
PMC: 6769380.
DOI: 10.15252/embj.201796659.
View
13.
Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L
. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019; 104(6):2367-2374.
DOI: 10.1210/jc.2018-01968.
View
14.
Pacak K
. New Biology of Pheochromocytoma and Paraganglioma. Endocr Pract. 2022; 28(12):1253-1269.
PMC: 9982632.
DOI: 10.1016/j.eprac.2022.09.003.
View
15.
Toledo R, Burnichon N, Cascon A, Benn D, Bayley J, Welander J
. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2016; 13(4):233-247.
DOI: 10.1038/nrendo.2016.185.
View
16.
Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu S, Max A, Pouget C
. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019; 474(6):721-734.
DOI: 10.1007/s00428-019-02553-5.
View
17.
Carrasquillo J, Chen C, Jha A, Pacak K, Pryma D, Lin F
. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. J Nucl Med. 2021; 62(9):1192-1199.
PMC: 8882896.
DOI: 10.2967/jnumed.120.259697.
View
18.
Zelinka T, Musil Z, Duskova J, Burton D, Merino M, Milosevic D
. Metastatic pheochromocytoma: does the size and age matter?. Eur J Clin Invest. 2011; 41(10):1121-8.
PMC: 3170415.
DOI: 10.1111/j.1365-2362.2011.02518.x.
View
19.
Comino-Mendez I, Tejera A, Curras-Freixes M, Remacha L, Gonzalvo P, Tonda R
. ATRX driver mutation in a composite malignant pheochromocytoma. Cancer Genet. 2016; 209(6):272-7.
DOI: 10.1016/j.cancergen.2016.04.058.
View
20.
Taieb D, Jha A, Treglia G, Pacak K
. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019; 26(11):R627-R652.
PMC: 7002202.
DOI: 10.1530/ERC-19-0165.
View